Sertranorm

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sertranorm

What is Sertranorm?

Sertranorm is a pharmaceutical medication containing the active substance sertraline. It belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). These medications are primarily utilized to manage various mood and anxiety-related conditions by influencing the chemical balance in the brain.

Mechanism of Action

The active ingredient in Sertranorm works by increasing the levels of serotonin, a neurotransmitter, in the central nervous system. Serotonin plays a significant role in regulating mood, sleep, and emotional stability. By inhibiting the reabsorption (reuptake) of serotonin into the nerve cells, the medication allows more of this chemical to remain available in the gaps between cells, which helps improve the transmission of nerve impulses and stabilizes emotional states.

Therapeutic Applications

Sertranorm is commonly used in the treatment of several psychological conditions, including:

  • Depressive Disorders: It is used to alleviate symptoms of clinical depression and help prevent the recurrence of depressive episodes.
  • Panic Disorder: It helps manage the physical and emotional symptoms associated with sudden, intense periods of fear or panic.
  • Social Anxiety Disorder: It is applied in cases where individuals experience excessive self-consciousness and fear in social situations.
  • Obsessive-Compulsive Disorder (OCD): It is used to reduce the frequency and intensity of persistent, unwanted thoughts and repetitive behaviors.
  • Post-Traumatic Stress Disorder (PTSD): It assists in managing the long-term emotional effects following a traumatic event.

Product Characteristics

As an SSRI, Sertranorm is designed for long-term management rather than immediate relief. It is typically available in tablet form and is formulated to maintain a steady concentration of the active ingredient in the bloodstream. While it is effective for many individuals, its impact on brain chemistry occurs gradually over several weeks.

Regulatory References

  1. EMA Public Assessment Report: Sertraline

What side effects are possible with Sertranorm?

Possible Side Effects and Safety Information

Safety information for Sertranorm (Sertraline) is derived from official regulatory documentation, which classifies potential effects by frequency and the body system affected. Adverse reactions are grouped into categories such as Very Common, Common, and Rare, based on incidence rates observed in clinical data.


Classification of Officially Documented Adverse Reactions

Adverse reactions are formally organized into specific System-Organ Classes (SOCs). Very Common (1/10 of patients) effects, as noted in regulatory sources, include nausea, diarrhoea, insomnia, dizziness, headache, ejaculatory failure, and fatigue. Common effects (1/100 to < 1/10) include tremor, dry mouth, constipation, increased sweating, and decreased libido.


Documented Serious Adverse Reactions

Official labeling identifies specific serious, albeit rare, events. These include Serotonin Syndrome, a potentially life-threatening condition associated with the accumulation of serotonin, and Abnormal Bleeding, particularly gastrointestinal haemorrhage. The rare effect of Hyponatraemia (low blood sodium levels) and the potential for QT-interval prolongation are also documented in regulatory sources.


Safety Considerations for Specific Populations and Duration

Regulatory documents include specific safety statements for certain groups. For pediatric patients, increased reports of hostility and suicidal ideation are noted. Older adults are associated with an elevated risk for clinically significant hyponatraemia and bleeding. Furthermore, the risk of suicidal thoughts and behaviours is explicitly documented to be highest early during treatment or following a dosage adjustment, which defines a critical time-related safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory labeling states that a Sertranorm (Sertraline) overdose may present with a range of documented clinical signs and manifestations. The information below is based strictly on the official overdose sections published by government regulatory authorities.

Documented Overdose Manifestations

The officially recognized signs include central nervous system (CNS) effects such as drowsiness, somnolence, lethargy, tremor, and confusion. Gastrointestinal manifestations typically involve nausea and vomiting. Cardiovascular signs reported in regulatory documents include tachycardia (increased heart rate) and palpitations.

Severe Outcomes and Emergency Action

Severe, life-threatening outcomes are explicitly documented and require immediate intervention. These include the specific risk of Serotonin Syndrome, characterized by symptoms like muscle rigidity, hyperthermia, and rapid heart rate. Other serious manifestations include seizure, syncope (fainting), and potentially dangerous cardiac rhythm changes like QTc prolongation. Immediate medical attention must be sought for any suspected overdose. Emergency care is specifically required if signs of Serotonin Syndrome or seizure are present. Regulators note that the severity of overdose is often increased by the co-ingestion of alcohol or other serotonergic agents.

Official Management Strategy

Official labeling confirms that no specific antidote is known for Sertraline overdose. Management, therefore, consists entirely of symptomatic and supportive treatment. Regulatory guidance mandates close clinical monitoring, and procedures such as securing an adequate airway, ventilation, and oxygenation are critical. Procedures like gastric lavage or activated charcoal may be considered for recent ingestion, as described in official documents.

Therapeutic Uses of Sertranorm

Sertranorm is commonly used in situations involving certain distressing symptoms across several therapeutic domains. It may be part of symptomatic management in conditions where patients experience psychological or emotional distress.

Relief from Persistent Depressive States

The medication is commonly used across conditions presenting with acute episodes like Major Depressive Disorder (MDD), and may assist with managing symptoms related to persistently low mood, feelings of hopelessness, and the loss of pleasure in daily life. It is applied across domains where additional symptomatic support is needed and provides support that helps ease the overall symptom burden. The medication is used for the treatment of Major Depressive Disorder (MDD).

Management of Acute and Chronic Anxiety

Sertranorm provides supportive therapeutic benefit across various anxiety disorders, including Panic Disorder, Social Anxiety Disorder, and Posttraumatic Stress Disorder (PTSD). It is commonly used to help with managing symptom intensity related to unexpected panic attacks, social fears, and trauma-related manifestations like flashbacks and hyperarousal. It is relevant in contexts involving heightened systemic burden and recurring episodes of fear that interfere with daily functioning.

Easing Obsessive-Compulsive Manifestations

This medication is utilized for Obsessive-Compulsive Disorder (OCD), a condition where symptom clusters may become intense or disruptive, such as distressing, intrusive obsessive thoughts and repetitive, anxiety-reducing compulsive rituals. It is relevant for easing the symptomatic discomfort and supports patients, including children and adolescents, during difficult episodes by easing distress related to these ritualized behaviors.

Quick Fact: Support for Symptom Stabilization

Sertranorm is used in settings where short-term symptom stabilization is important across conditions characterized by periods of heightened symptoms, including MDD and OCD.

Eligibility and Restrictions for Use

Who can and cannot use Sertranorm

Eligibility to use Sertranorm (Sertraline) is determined by regulatory agencies based on age, co-administration status, and specific pre-existing conditions.

Absolute Non-Eligibility (Contraindications): Sertranorm is strictly prohibited for patients with known hypersensitivity to the drug's components. It is also contraindicated for individuals currently taking Monoamine Oxidase Inhibitors (MAOIs), or those who have discontinued an MAOI within the last 14 days, and for patients taking Pimozide.

Age-Based Eligibility: Use is approved for adults across all labeled indications. In the pediatric population, it is only approved for Obsessive-Compulsive Disorder (OCD) in children and adolescents aged 6 to 17 years; safety and effectiveness for other uses have not been established in this age group. Young adults aged 24 and under require close monitoring.

Population Restrictions and Conditional Use: The medicine is not recommended for patients with severe hepatic impairment (severe liver disease) or unstable epilepsy. Use must proceed with caution in patients with a history of seizure disorders, mania/hypomania, or certain cardiovascular risks, such as QTc prolongation factors. Use during the third trimester of pregnancy is restricted, and the drug is known to be excreted in human milk.

What should I know about interactions with other medicines?

Official Contraindications and Timing Rules

Co-administration of Sertranorm (Sertraline) is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including irreversible MAOIs, the antibiotic Linezolid, and intravenous Methylene Blue, due to the high risk of Serotonin Syndrome. Pimozide and Thioridazine are also prohibited combinations documented in regulatory labels.

A minimum 14-day washout period is required when switching between Sertranorm and an irreversible MAOI. When switching to a reversible MAOI, at least 7 days must elapse after Sertranorm discontinuation, as defined in official timing rules.


Pharmacodynamic and Exposure Interactions

Concomitant use with other serotonergic agents (such as Triptans or Tramadol) increases the documented risk of Serotonin Syndrome. Combining Sertraline with agents that affect platelet function, such as NSAIDs, Aspirin, or Warfarin, is associated with an increased risk of bleeding. Warfarin co-administration requires monitoring of prothrombin time.

Sertraline is a documented mild-to-moderate inhibitor of the CYP2D6 enzyme, which can increase the exposure of co-administered substrates of this enzyme. Plasma concentrations of Phenytoin may be increased by Sertraline. Reduced clearance, leading to approximately 3-fold greater exposure, is documented in patients with hepatic impairment.


Food and Substance Interactions

The use of alcohol is not recommended. The herbal product St. John’s Wort should be avoided due to the potential for enhanced serotonergic effects. Grapefruit juice has been reported to increase the medication's blood levels.

Mechanism of Action

Molecular Action: Selective Serotonin Transporter Inhibition

The drug initiates its effect by directly engaging the Serotonin Transporter (SERT) protein in the brain, acting as a highly specific inhibitor. This action rapidly blocks the reuptake of the neurotransmitter serotonin from the synaptic cleft, immediately increasing serotonergic signaling.


Functional Cascade: Time-Dependent Neuroplasticity

The core functional cascade is driven by the brain’s delayed adaptation to this sustained increase in serotonin. This adaptation includes the downregulation of inhibitory presynaptic autoreceptors, which subsequently removes a regulatory constraint on serotonin release. This sustained, increased signaling drives crucial neuroplastic changes, fostering neurogenesis (new neuron growth) and remodeling neural circuits, resulting in chronic alterations to central nervous system pathways.


Supporting Modulation and Biological Constraints

Sertraline's overall pharmacological activity also involves minor modulation of other targets, such as the Sigma-1 (σ1) receptor. Crucially, the functional outcome of the primary mechanism can be biologically limited by individual genetic variability in tryptophan metabolism or SERT expression, which describes variability in the resulting physiological modulation.

Dosage and Administration Information

How to Use Sertranorm

The administration of Sertranorm, which contains the active ingredient sertraline, follows specific guidelines. These details define the method, frequency, and maximum amounts for use.


Administration Scope

Feature Administration Details
Route of Administration Sertranorm is designated for oral administration only.
Dosing Schedule The standard starting dose for most uses is 50 mg once daily. For certain conditions, a lower starting dose of 25 mg is used. The maximum recommended daily dose is 200 mg.
Timing in Relation to Meals Tablets may be taken with or without food.
Preparation Requirements The 20 mg/mL oral concentrate form must be diluted immediately prior to intake with 4 ounces of liquid, such as water or citrus beverages.
Age-Group Administration Pediatric use for Obsessive-Compulsive Disorder (OCD) typically begins with 25 mg/day for children (6-12 years) and 50 mg/day for adolescents.
Special Procedural Conditions Dose adjustments, if required, must be separated by a minimum of one week and increased by no more than 50 mg increments to control the rate of dose change.

Procedural Structure

The use protocol involves taking Sertranorm once daily. The dose is initiated at a low, defined amount and any subsequent adjustments are governed by a one-week minimum interval to control the overall course. The protocol for tablets is flexible regarding food intake, but the oral concentrate requires immediate dilution with an approved liquid before consumption. This structured approach ensures adherence to the established maximum daily limits and titration rate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sertranorm

This section provides an overview of the official research structure used to evaluate Sertranorm, focusing on study types, populations, and outcomes examined, without offering clinical guidance or interpretation.


Evidence for Use in Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Research exploring how symptoms change over time has involved Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses. These studies have primarily been used in research examining symptom intensity or variability in individuals diagnosed with Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)—conditions associated with acute or disruptive episodes.

For MDD, studies monitored patient-reported outcomes describing perceived discomfort and functional imbalance. Research highlights changes measured during the study period on severity scales used to monitor symptoms such as low mood and loss of pleasure. Findings describe patterns observed in the studies, and some trials monitored symptom scores in research scenarios involving different types of intervention. Data show patterns related to symptom changes observed in the study populations. Limited information for long-term outcomes in MDD is still being developed.

For OCD, research examined episodic symptom patterns across both adults and children. Studies explored outcomes related to the intensity of intrusive thoughts and compulsive behaviors. Research describes observations in long-term continuation trials that monitored status over time. Data for highly treatment-refractory groups are still emerging.

Research on Panic Disorder and Social Anxiety Disorder

Research has evaluated the medicine for conditions characterized by fluctuating or episodic manifestations, such as Panic Disorder and Social Anxiety Disorder (SAD). Studies monitored short-term symptom changes, examining outcomes related to episodic or acute symptom activity.

For Panic Disorder, research describes how the frequency of panic attacks was measured; studies reported patient-described patterns related to a global assessment of their condition. Findings describe patterns observed in the studies where measurement data were collected over defined time intervals. Research exploring long-term prevention of symptom recurrence beyond a year is not fully established.

Research on Posttraumatic Stress Disorder (PTSD)

Studies were conducted during periods of increased symptom activity in adults with Posttraumatic Stress Disorder (PTSD). Research examined outcomes related to physiological strain and stress, specifically tracking the three core symptom axes: intrusion, avoidance, and hyperarousal. Findings were mixed in certain subgroups, such as those involving veterans, where data collected reflected a range of observations. Data for children and adolescents are still emerging.


Research Gaps and What Remains Uncertain

While research describes various patterns observed, evidence quality varies across studies, and findings were mixed for certain complex subgroups. Long-term effects are not fully established across all conditions, and limited information remains regarding the comparative evidence available. Research highlights what is known—and what is still uncertain—and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Depression in adults: recognition and management (NICE Guideline NG222)

Frequently Asked Questions (FAQ)

Common questions about Sertranorm (FAQ)


Q: How long does it typically take for Sertranorm to start showing effects?

A: Clinical studies indicate that the onset of beneficial effects is generally gradual. Treatment may require several weeks before any positive changes are observed.

Q: When is the full benefit of Sertranorm generally expected?

A: The full clinical benefit is often expected to become apparent after the initial adjustment period. Beneficial effects are typically noticed after four to six weeks of consistent therapy.

Q: Is it common to feel worse during the first few weeks after starting Sertranorm?

A: Official warnings state that a person’s family should monitor for the emergence of new or worsening feelings at the start of treatment. These changes may include anxiety, agitation, restlessness, irritability, or panic.

Q: What are the potential effects of abruptly stopping Sertranorm?

A: Official warnings advise against abruptly stopping the medication or significantly lowering the dose because it can cause symptoms sometimes grouped as Antidepressant Discontinuation Syndrome. These symptoms may include dizziness, nausea, sensory disturbances, or anxiety.

Q: Are sexual side effects of Sertranorm permanent or long-lasting?

A: While sexual side effects often resolve after stopping the medicine, regulatory reviews have noted rare cases where long lasting sexual symptoms persisted after discontinuation. These effects were reported to last potentially for weeks to years.

Q: Does Sertranorm typically lead to weight gain or weight loss?

A: Studies examining adults over six to twelve months often reported a small amount of weight gain in the study population. Conversely, in pediatric studies, weight loss and a decrease in expected weight gain were reported as effects.

Q: Is a change in appetite a common effect of Sertranorm?

A: Official safety information reports that a change in appetite is a documented side effect. This may manifest as a loss of appetite (anorexia) or, in some cases, as an increased appetite.

Q: What happens if a person misses a single dose of Sertranorm?

A: Official regulatory instructions describe the procedure for a missed dose: if remembered soon, the dose may be taken. If it is nearly time for the next scheduled dose, the missed dose is instructed to be skipped entirely to prevent taking two doses close together.

Q: What is the time window for the adjustment period when first starting Sertranorm?

A: Studies and official information indicate that a time-dependent process is required for the full effect of the medicine. While the body begins adapting quickly, beneficial effects on symptoms may require several weeks of therapy to appear. The onset of action is often noticed by patients after approximately four to six weeks of consistent use.

Q: What is Serotonin Syndrome and is it a reported risk with Sertranorm?

A: Serotonin Syndrome is a serious, rare condition documented in official safety information. It is associated with the accumulation of the neurotransmitter serotonin in the body. Symptoms may include extreme anxiety, high fever, excessive sweating, confusion, or muscle rigidity.

Q: Is it better to take Sertranorm in the morning or in the evening?

A: Official regulatory instructions state that Sertranorm should be taken once daily. The timing of administration is flexible, meaning it can be taken either in the morning or in the evening, depending on the daily routine.

Q: What specific conditions is Sertranorm approved to treat according to regulatory bodies?

A: The medicine is officially approved to treat several conditions. These generally include Major Depressive Disorder, Panic Disorder, Posttraumatic Stress Disorder (PTSD), and Social Anxiety Disorder. It is also approved for Obsessive-Compulsive Disorder (OCD) and Premenstrual Dysphoric Disorder (PMDD).

Q: What is the research status regarding Sertranorm use during pregnancy?

A: Official warnings discuss the use of Sertranorm during pregnancy. Taking the medicine, particularly in the last three months, may increase the risk of the newborn developing a serious lung condition. This condition is known as Persistent Pulmonary Hypertension of the Newborn (PPHN).

Q: Does Sertranorm interact with common over-the-counter pain relievers?

A: Official warnings note a specific interaction with over-the-counter medicines that affect blood platelet function. Co-administration with agents like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Aspirin is associated with an increased risk of abnormal bleeding, particularly gastrointestinal haemorrhage.

Q: Does Sertranorm interact with common herbal supplements or vitamins?

A: Regulatory warnings state that the herbal product St. John’s Wort should be avoided. This is due to the potential for enhanced serotonergic effects, which refers to an excessive increase in serotonin signaling.

Q: Are there risks associated with taking Sertranorm for many years?

A: Research on the effects of long-term use is still being developed across all conditions. Official reviews have noted rare cases where certain side effects, including sexual symptoms, have been long lasting (potentially persisting for weeks to years) even after treatment was stopped.

Q: Is Sertranorm considered a tranquilizer or sedative?

A: Sertranorm is classified pharmacologically as an antidepressant and specifically belongs to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). It is not categorized as a tranquilizer or sedative in official documentation.

Q: What are the most frequently reported sexual side effects in men taking Sertranorm?

A: Regulatory data indicates that frequently reported sexual side effects in men include ejaculation failure and decreased sexual desire (libido). Erectile dysfunction is also commonly reported in clinical trials.

Q: What are the most frequently reported sexual side effects in women taking Sertranorm?

A: According to adverse reaction tables, decreased sexual desire (libido) is a frequently reported effect in women. Other forms of female sexual dysfunction have also been reported in safety data.

Q: Can Sertranorm affect a person's ability to drive or operate heavy machinery?

A: Common adverse effects of the medicine include dizziness and fatigue. These documented effects may temporarily affect a person's judgment or motor skills, potentially impacting the ability to safely drive or operate complex machinery.

Q: What are the possible effects of Sertranorm on a person's vision or eyes?

A: Documented eye-related effects include blurred vision, dry eyes, and pupillary dilation. Official warnings also note a rare risk of angle-closure glaucoma for certain individuals who are susceptible to that condition.

Q: Is Sertranorm sometimes prescribed for premenstrual dysphoric disorder (PMDD)?

A: Yes, Sertranorm has specific regulatory approval for use in relieving the symptoms of Premenstrual Dysphoric Disorder (PMDD). This use is documented in official labeling from bodies like the FDA.

Q: What are the signs that a person's symptoms may be worsening on Sertranorm?

A: Regulatory warnings state that monitoring is advised for signs that symptoms may be worsening, especially during the initial phase of treatment. These signs include new or worsening thoughts of suicide, or sudden changes in feelings such as agitation, hostility, panic, or extreme restlessness.

Q: Is 'emotional blunting' or feeling numb a reported effect of Sertranorm?

A: Clinical safety data reports that emotional blunting is an associated adverse effect of SSRI medicines. This effect involves experiencing a restricted range of emotions or feeling a sense of being numb or detached.

Q: Is Sertranorm used for conditions other than mental health disorders?

A: The majority of approved uses are for various mental health disorders. However, it is also officially approved for Premenstrual Dysphoric Disorder (PMDD), which is sometimes viewed as a condition separate from the core psychiatric indications.

How should Sertranorm be stored and disposed of?

How to Store and Dispose of Sertranorm

The storage and disposal of Sertranorm (sertraline hydrochloride tablets) must adhere strictly to regulatory requirements to maintain product integrity and ensure safety.


Official Storage Conditions

Sertraline tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F), with a permitted range of 15°C to 30°C (59°F to 86°F). The medication must be kept in its original container with the cap tightly closed to protect it from moisture. It is mandatory that Sertranorm is kept out of the sight and reach of children and pets, and away from excess heat or freezing temperatures.

Disposal Instructions

Official guidelines recommend disposing of unused or expired Sertranorm through an authorized drug take-back program. If a take-back option is unavailable, the medicine should be removed from its container, mixed with an undesirable substance (like coffee grounds), sealed in a bag, and then placed in the household trash; the medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertranorm found in:

A-Z Index: